The Accord/ Intas groups total network operates 12 sites with supply to the EUMENA market from 6 significant EU GMP and USFDA approved sites. This includes the Intas sites SEZ, Matoda, Moraiya and Dehradun. Our manufacturing and supply chain capability is core to our business. Intas currently manufactures over 20 billion tabs worldwide and continues to invest in manufacturing production further.
Oral solid dose capabilities include Oncology and Immune Suppressants as well as regular tablets, capsules, effervescent and other formulations. Parenteral capabilities include regular and cytotoxic solution and lyophilised vials as well as controlled drug products.